Genmab (GMAB) has released an update.
Genmab A/S, the Copenhagen-based biotech firm, has updated its Articles of Association to reflect new authorizations for capital increases and the issuance of warrants and convertible debt instruments until March 2029. The company is focused on medical research, production, and sale of related products, and has provisions for capital increases both with and without pre-emption rights for existing shareholders, emphasizing its commitment to growth and employee incentives.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
